Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40
Tango Therapeutics, Inc.
Tango Therapeutics, Inc. TNGX | 0.00 |
Mizuho analyst Joseph Catanzaro maintains Tango Therapeutics (NASDAQ:
TNGX) with a Outperform and raises the price target from $36 to $40.
